Supreme Court Blocks Apotex Glaucoma Drug Invalidity Appeal
The U.S. Supreme Court on Monday refused to consider Apotex Inc.'s appeal of a lower court's ruling that Allergan Inc.'s glaucoma eyedrop formulation patents are not obvious in a suit accusing...To view the full article, register now.
Already a subscriber? Click here to view full article